Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder — Stella

Home/Autism Spectrum Disorder/Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

View on ClinicalTrials.gov

Recruiting

Back to Autism Spectrum Disorder trials

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

University of Kansas, Center for Research, Lawrence, Kansas

Center for Autism and the Developing Brain, White Plains, New York

Key details

Phase

Safety & dosing

Sponsor

New York State Psychiatric Institute

Collaborators

ACADIA Pharmaceuticals Inc., University of Kansas Medical Center

Enrollment target

~30 participants

Started

October 2025

Primary completion

December 2026

Age range

12 Years – 40 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.